Ultime notizie per Ventas (NYSE:VTR) Azioni

Ventas

Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Ventas Inc

VETROPACK HLDF ST PRX A by Vetropack Holding SA

Vitrolife AB

VECTRON SYSTEMS AG NEW by Vectron Systems AG New

Vectron Systems AG

Vitro Biopharma, Inc

Viatris Inc

VIATRIS ORD

VECTOR INC TOKYO by Vector Inc.

Vitru Ltd

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 4.08% since its last report. The company recently reported that it has 10.20 million shares sold short, which is 3.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729170919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Ventas's Recent Short Interest

In the preceding three months, 9 analysts have released ratings for Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.78, a high estimate of $71.00, and a low estimate of $56.00. This current average reflects an increase of 11.48% from the previous average price target of $58.11. 
<img src="https://www.benzinga.com/files/images/story/2024/1728662429_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ventas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ventas. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ventas's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Ventas's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Discovering Ventas: A Closer Look</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Unraveling the Financial Story of Ventas</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Ventas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.2%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ventas's ROA stands out, surpassing industry averages. With an impressive ROA of 0.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Scoreboard: 9 Ratings For Ventas

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $59 to $65.

News

Price Target

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $65

Wells Fargo analyst John Kilichowski assumes Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Overweight rating and raises Price Target to $71.

Initiation

Wells Fargo Assumes Ventas at Overweight, Raises Price Target to $71

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 25.59% since its last report. The company recently reported that it has 9.80 million shares sold short, which is 3.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727718313_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

7 analysts have expressed a variety of opinions on Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $63.86, a high estimate of $71.00, and a low estimate of $56.00. This current average has increased by 10.93% from the previous average price target of $57.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1726506024_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Ventas's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Ventas's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Get to Know Ventas Better</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Ventas's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Ventas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Ventas's net margin is impressive, surpassing industry averages. With a net margin of 1.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ventas's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.2%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.08%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.39, Ventas adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Ventas In The Eyes Of 7 Experts

Evercore ISI Group analyst Steve Sakwa maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $64 to $70.

Evercore ISI Group Maintains Outperform on Ventas, Raises Price Target to $70

Real Estate

Ventas Enters Agreements With Kindred And ScionHealth Including Regarding 23 Long Term Acute Care Hospitals Whose Lease Term Is Scheduled To Mature On Apr. 30; Initial Annualized Cash Contractual Base Rent For The LTACS Will Be $80M Starting May 1, 2025, Consistent With The Company's Previously Announced Expectations, And Rent Will Escalate Annually By 2.75% Through The Extended Lease Maturity Date Of April 30, 2030

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 3.41% since its last report. The company recently reported that it has 7.80 million shares sold short, which is 2.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725973213_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 3.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Wedbush analyst Richard Anderson maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $64 to $71.

Wedbush Maintains Outperform on Ventas, Raises Price Target to $71

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $61.2, a high estimate of $64.00, and a low estimate of $56.00. This upward trend is apparent, with the current average reflecting a 11.27% increase from the previous average price target of $55.00.
<img src="https://www.benzinga.com/files/images/story/2024/1724871652_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ventas by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ventas's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>All You Need to Know About Ventas</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Ventas: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.55%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ventas's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.2%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.08%, the company showcases effective utilization of assets.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Ventas's Future

Evercore ISI Group analyst Steve Sakwa maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $61 to $64.

Evercore ISI Group Maintains Outperform on Ventas, Raises Price Target to $64

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 3.12% since its last report. The company recently reported that it has 7.86 million shares sold short, which is 2.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723233613_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 6.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Ventas?

RBC Capital analyst Michael Carroll maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $52 to $63.

RBC Capital Maintains Outperform on Ventas, Raises Price Target to $63

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $55 to $59.

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $59

Wedbush analyst Richard Anderson maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $54 to $64.

Wedbush Maintains Outperform on Ventas, Raises Price Target to $64

As of Aug 5, 2024, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Ventas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>)</h3>
<ul>
<li>On Aug. 1, Ventas posted better-than-expected quarterly results. &#8220;We started 2024 with momentum, which continued in the second quarter as we delivered another quarter of strong results. We are executing on our focused strategy to capture the unprecedented multiyear growth opportunity in senior housing,&#8221; said Debra A. Cafaro, Ventas Chairman and CEO. The company's stock gained around 8% over the past month and has a <a href="https://www.benzinga.com/quote/VTR">52-week high of $57.16</a>.</li>
<li>RSI Value: 78.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VTR Price Action: Shares of Ventas gained 0.3% to trade at $56.54 on Monday.</li>
</ul>
<h3 class="wp-block-heading">American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>)</h3>
<ul>
<li>On July 30, American Tower reported better-than-expected second-quarter financial results. Steven Vondran, American Tower&#8217;s Chief Executive Officer, stated, &#8220;The momentum from the start of the year extended into Q2, with core results highlighting the strong underlying demand for our portfolio of communications assets. Positive collection trends further accelerated in India, our U.S. &amp; Canada segment delivered over 5% Organic Tenant Billings Growth and CoreSite achieved its second highest quarter of signed new business on record, all supporting over 13% Attributable AFFO per Share growth in the quarter, and our ability to raise the midpoints of the key financial measures in our updated 2024 outlook.&#8221; The company's stock gained around 18% over the past month and <a href="https://www.benzinga.com/quote/AMT">has a 52-week high </a>of $236.13.</li>
<li>RSI Value: 73.03</li>
<li>AMT Price Action: Shares of American Tower fell 2% to trade at $230.00 on Monday.</li>
</ul>
Read More:<a href="https://www.benzinga.com/news/24/08/40161976/home-depot-to-rally-more-than-14-here-are-10-top-analyst-forecasts-for-monday"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40161976/home-depot-to-rally-more-than-14-here-are-10-top-analyst-forecasts-for-monday">Home Depot To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

Markets

Top 2 Real Estate Stocks That May Dip In August

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.79 by 1.27 percent. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.19 billion by 0.54 percent. This is a 8.59 percent increase over sales of $1.11 billion the same period last year.

Earnings

Earnings Beats

Ventas Q2 2024 FFO $0.80 Beats $0.79 Estimate, Sales $1.20B Beat $1.19B Estimate

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 6.57% since its last report. The company recently reported that it has 7.61 million shares sold short, which is 2.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721240115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 6.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(VTR) - Analyzing Ventas's Short Interest

Evercore ISI Group analyst Steve Sakwa maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $53 to $56.

Evercore ISI Group Maintains Outperform on Ventas, Raises Price Target to $56

Life science space supply far outstrips demand, fueling higher office vacancy rates

Lazard Real Assets Portfolio Q2 2024 Commentary

Ventas (VTR – Research Report) received a Buy rating and a $71.00 price target from Wells Fargo analyst James Feldman today. The company's shares c...

Ventas (VTR) was upgraded to a Buy Rating at Wells Fargo

Wells Fargo upgrades 3, downgrades 2 healthcare REITs on price to earnings growth and yield

Real estate stocks end in red amid geopolitical tensions

An October Surprise

Hurricane Milton puts $30B of Florida muni debt at risk - report

The combination of demographic trends, increasing healthcare needs, and stable revenue structures makes the healthcare REITs industry poised for robust growth. Therefore, it could be wise to explore investments in robust REITs such as Ventas (VTR), Omega Healthcare Investors (OHI), and National Health Investors (NHI). Keep reading… Investing in healthcare REITs can offer a unique opportunity for stable income and portfolio diversification, thanks to the essential nature of healthcare services. Therefore, high-potential REITs Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>), Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>), and National Health Investors, Inc. (<a href="https://stocknews.com/stock/NHI/">NHI</a>) might be worthy watchlist additions.
Healthcare Real Estate Investment Trusts (REITs) are a dynamic sector within the real estate market, focusing on properties such as hospitals, nursing facilities, senior housing, and medical office buildings. These REITs are poised for strong performance, especially as the <a href="https://www.reit.com/news/articles/aging-of-us-population-to-provide-strong-demand-for-health-care-reits">aging U.S. population drives increased demand</a> for healthcare services and senior living facilities.
Healthcare is a stable market, providing stable occupancy rates and reliable income streams for these REITs. The shift toward outpatient services, along with technological advancements in medical care, further supports the demand for modern healthcare facilities. Furthermore, the REIT market is poised to reach $333.01 billion by 2027, growing at a <a href="https://www.technavio.com/report/reit-market-analysis">CAGR of 2.8%</a>.
Considering these conducive trends, let's take a look at the fundamentals of the three choices from the <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> industry, starting with third in line.
Stock #3: Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>)
VTR is a leading S&amp;P 500 real estate investment trust enabling exceptional environments that benefit a growing aging population. With approximately 1,350 properties in North America and the United Kingdom, the trust occupies an essential role in the longevity economy.
On September 16, 2024, VTR announced that it has entered into agreements with Kindred Healthcare, LLC and its parent companies, including regarding the 23 long-term acute care hospitals whose lease term is scheduled to mature on April 30, 2025, under the existing Master Lease between Ventas and Kindred.
VTR pays $1.80 annually, which translates to a yield of 2.89% on the prevailing price level. Its four-year average dividend yield is 3.78%.
VTR's total revenues increased 6.8% year-over-year to $1.20 billion during the second quarter ended June 30, 2024. Its net income was reported at $21.17 million, and net income per share attributable to common stockholders at $0.05.
Street expects VTR's revenue for the third quarter that ended September 2024 to increase 5.5% year-over-year to $1.21 billion. For the same quarter, the company's EPS is expected to grow 5.8% year-over-year to $0.79. Furthermore, the company surpassed the consensus revenue and FFO estimates in each of the trailing four quarters.
VTR's stock has gained 28.1% over the past nine months and 57.3% over the past year to close the last trading session at $62.38.
It's no surprise that VTR has a B grade for Momentum, as reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree. It is ranked #8 out of 14 stocks in the <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> industry. 
To see additional POWR Ratings for Value, Sentiment, Stability, and Growth, <a href="https://stocknews.com/stock/VTR/">click here</a>.
Stock #2: Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>)
OHI is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. 
OHI pays $2.68 annually, which translates to a yield of 6.78% on the prevailing price level. Its four-year average dividend yield is 8.48%.
OHI's total revenues for the fiscal second quarter that ended June 30, 2024, increased 6.5% year-over-year to $252.75 million. Net income and earnings per share stood at $117.08 million and $0.45, up 90.2% and 80% year-over-year, respectively.
For the third quarter ended September 2024, OHI's revenue is expected to increase 5% year-over-year to $216.15 million. Its FFO for the same quarter is expected to be $0.71. OHI surpassed the consensus FFO estimates in each of the trailing four quarters. 
OHI gained 17% over the past three months to close its last trading session at $39.51.
OHI has a B grade for Momentum and Quality. It is ranked #3 in the same industry.
For additional OHI's Growth, Stability, Sentiment, and Value, click <a href="https://stocknews.com/stock/OHI/">here</a>.
Stock #1: National Health Investors, Inc. (<a href="https://stocknews.com/stock/NHI/">NHI</a>)
NHI is a real estate investment trust specializing in sales, leasebacks, joint ventures, senior housing operating partnerships, and mortgage and mezzanine financing of discretionary senior housing and medical investments. The company's portfolio comprises independent living, assisted living and memory care communities, skilled nursing facilities, and specialty hospitals.
NHI pays $3.60 annually, which translates to a yield of 4.44% on the prevailing price level. Its four-year average dividend yield is 6.45%.
NHI's total revenues for the second quarter ended June 30, 2024, were reported at $84.97 million, up 9.1% year-over-year. Net income attributable to stockholders was reported at $35.23 million, and earnings per common share was $0.81.
Street expects NHI's revenue for the quarter ending December 2024 to increase 3.4% year-over-year to $85.35 million. Its <a href="https://www.investopedia.com/terms/d/dilutedeps.asp">EPS</a> is expected to be $1.14 for the same quarter. NHI surpassed the consensus revenue estimates in each of the trailing four quarters, which is impressive.
The stock gained 51.4% over the past nine to close the last trading session at $81.37.  
NHI has a B grade for Momentum, Stability, and Quality. It is ranked first in the same industry.
Beyond what is stated above, we've also rated NHI for Value, Growth, and Sentiment. Get all NHI ratings <a href="https://stocknews.com/stock/NHI/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
VTR shares were trading at $62.22 per share on Wednesday afternoon, down $0.16 (-0.26%). Year-to-date, VTR has gained 28.16%, versus a 22.29% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/vtr-ohi-nhi-3-healthcare-reits-offering-growth-and-income-potential/>3 Healthcare REITs Offering Growth and Income Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare REITs Offering Growth and Income Potential

REITs drag real estate stocks down

In a report released today, Ronald Kamdem from Morgan Stanley maintained a Hold rating on Ventas (VTR – Research Report), with a price target of $6...

Morgan Stanley Sticks to Their Hold Rating for Ventas (VTR)

AAPL

ACWI

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

BBRE

BKDT

BLDG

BXMT

CBRE

CHCT

CSGP

CTRE

CUBE

CURB

DFAR

DHCNI

DHCNL

EQIX

FREL

GQRE

HAUS

HAUZ

HOMZ

IFGL

INDS

INVH

IRET

JPRE

KBWY

LAND

LANDM

LANDO

LANDP

MORT

NAIL

NETL

NURE

NVDA

NXRT

PFFR

PLDGP

PPTY

RDOG

REET

REGCO

REGCP

REIT

RIET

ROOF

RSPR

SBAC

SBRA

SCHH

SITC

SPRE

SRVR

SSEZF

SSEZY

STWD

TRGP

USRT

VCISF

VCISY

VICI

VIOO

VRAI

WELL

XLRE

Press Releases

Ventas Issues Business Update

Ventas to Present at Nareit's REITweek 2024 Investor Conference

Ventas Announces Second Quarter 2024 Earnings Release Date and Conference Call

Ventas Reports 2024 Second Quarter Results

Ventas Announces Pricing of Senior Notes Offering

Ventas to Participate in Investor Meetings at BofA Securities 2024 Global Real Estate Conference

Ventas Releases 2023-2024 Corporate Sustainability Report

Ventas Reaches Agreements with Kindred and ScionHealth

Ventas Declares Third Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Announces Third Quarter 2024 Earnings Release Date and Conference Call

American Healthcare REIT, Inc. Common Stock

American Healthcares

Alexandria Real Estate Equities, Inc. Common Stock

Alexandria Real Estate

Community Healthcare Trust Incorporated Common Stock

Community Healthcare

CareTrust REIT

Diversified Healthcare Trust - Common Shares of Beneficial Interest

Diversified Healthcare

Healthpeak Properties

Global Medical REIT

Healthcare Realty Trust Incorporated Common Stock

Healthcare Realty Trust

LTC Properties

Medical Properties Trust, Inc. common stock

Medical Properties Trust

National Health Investors, Inc. Common Stock

National Health Investors

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Invts

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT

Sila Realty Trust

Strawberry Fields REIT, Inc. Common Stock

Strawberry Fields REIT

Universal Health Realty Income Trust Common Stock

Universal Health Realty

Welltower

Scotiabank

Wells Fargo

Evercore ISI Group

Wedbush

RBC Capital

Comments

Ventas

Notizie

Ultime notizie per Ventas (NYSE:VTR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO